Sanofi (EPA:SAN) has received a consensus recommendation of “Hold” from the seventeen analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is €87.24 ($101.44).
A number of equities analysts have issued reports on the stock. HSBC Holdings plc set a €81.00 ($94.19) target price on shares of Sanofi and gave the stock a “neutral” rating in a research report on Wednesday, August 30th. Jefferies Group LLC set a €87.00 ($101.16) target price on shares of Sanofi and gave the stock a “neutral” rating in a research report on Thursday, August 24th. Goldman Sachs Group, Inc. (The) set a €82.00 ($95.35) target price on shares of Sanofi and gave the stock a “neutral” rating in a research report on Monday, August 7th. Deutsche Bank AG set a €96.00 ($111.63) target price on shares of Sanofi and gave the stock a “buy” rating in a research report on Tuesday, August 1st. Finally, J P Morgan Chase & Co set a €90.00 ($104.65) target price on shares of Sanofi and gave the stock a “neutral” rating in a research report on Tuesday, August 1st.
Shares of Sanofi (EPA:SAN) traded down €0.36 ($0.42) on Friday, reaching €77.43 ($90.03). 2,440,000 shares of the company’s stock were exchanged, compared to its average volume of 1,870,000. Sanofi has a one year low of €73.39 ($85.34) and a one year high of €92.97 ($108.10).
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.truebluetribune.com/2017/11/28/sanofi-san-given-average-recommendation-of-hold-by-brokerages.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.